Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nukkleus ( (NUKK) ) has provided an announcement.
On December 30, 2025, Nukkleus Inc., via its Israeli subsidiary Nukk Picolo Ltd., completed the previously announced acquisition of all issued and outstanding shares of Tiltan Software Engineering Ltd. from seller Arie Shafir for a total consideration of NIS 47.6 million (about $14 million), making Tiltan an indirect wholly owned subsidiary. The deal structure combines a 75% cash component and 25% stock component, including a secured promissory note of NIS 29.75 million payable in five installments through June 29, 2026, a first-priority pledge over all Tiltan shares as collateral, escrow of up to 2 million Nukkleus common shares with value-adjustment mechanisms, and non‑competition and non‑solicitation covenants on the seller through June 2027, while a pre‑closing dividend to the seller will be funded during 2026 from select customer payments, collectively signaling a tightly structured, security‑backed transaction that spreads Nukkleus’s cash outlay over time while consolidating control over a vetted, audited Israeli software asset.
More about Nukkleus
Nukkleus Inc., a Delaware corporation, operates through subsidiaries including its wholly owned Israeli unit Nukk Picolo Ltd., and is expanding its presence in the Israeli technology and software sector through acquisitions such as Tiltan Software Engineering Ltd. Tiltan, an Israeli software engineering company whose financial statements are prepared under U.S. GAAP and audited by KPMG Somekh Chaikin, provides specialized software engineering services and operates with audited financials that indicate a going-concern basis as of year-end 2024 and 2023.
Average Trading Volume: 1,732,059
Technical Sentiment Signal: Sell
Current Market Cap: $70.41M
Learn more about NUKK stock on TipRanks’ Stock Analysis page.

